ValueQ4, 24TTMSelling/general/admin expenses——Research & development——Operating income-1.05 M-4.31 MNon-Operating Income, Total——Interest expense, net of interest capitalized——Non-Operating Income, excl. Interest Expenses——Unusual income/expense——Pretax income42.84 M17.48 BEquity in earnings——Taxes21.87 M-4.31 BNon-controlling/minority interest——After tax other income/expense——Net income before discontinued operations20.97 M21.79 BDiscontinued operations——Net income20.97 M21.79 BDilution adjustment——Preferred dividends——Diluted net income available to common stockholders20.97 M21.79 BBasic earnings per share (Basic EPS)——Diluted earnings per share (Diluted EPS)0.29191.05Average basic shares outstanding71.86 M—Diluted shares outstanding71.86 M—EBITDA——EBIT——Cost of revenue——Other cost of goods sold——Depreciation & amortization (cash flow)1.05 M4.31 M
Sinovac Biotech Ltd - (Antigua/Barbudo)
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China. Its COVID-19 vaccine was the target of a covert disinformation campaign by the US government and a promotional social media astroturfing campaign by the Chinese government.